Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.91
+1.7%
$4.79
$3.42
$6.91
$277.17M1.911.99 million shs819,254 shs
Amarin Corporation PLC stock logo
AMRN
Amarin
$15.33
+2.0%
$15.63
$7.08
$17.49
$317.02M0.7758,219 shs45,809 shs
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
$6.45
+5.6%
$4.54
$2.60
$7.77
$367.33M1.61180,417 shs258,711 shs
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$1.91
+18.6%
$1.21
$0.83
$5.39
$118.46M1.14638,329 shs2.22 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%-9.41%+9.60%-15.64%-9.24%
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%+1.93%+2.27%+24.33%+27.64%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
0.00%+16.64%+50.70%+64.96%+38.12%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
0.00%+49.22%+80.19%+41.48%-45.43%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.91
+1.7%
$4.79
$3.42
$6.91
$277.17M1.911.99 million shs819,254 shs
Amarin Corporation PLC stock logo
AMRN
Amarin
$15.33
+2.0%
$15.63
$7.08
$17.49
$317.02M0.7758,219 shs45,809 shs
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
$6.45
+5.6%
$4.54
$2.60
$7.77
$367.33M1.61180,417 shs258,711 shs
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$1.91
+18.6%
$1.21
$0.83
$5.39
$118.46M1.14638,329 shs2.22 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%-9.41%+9.60%-15.64%-9.24%
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%+1.93%+2.27%+24.33%+27.64%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
0.00%+16.64%+50.70%+64.96%+38.12%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
0.00%+49.22%+80.19%+41.48%-45.43%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.00
BuyN/AN/A
Amarin Corporation PLC stock logo
AMRN
Amarin
1.50
Reduce$12.00-21.72% Downside
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
0.00
N/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
2.67
Moderate Buy$7.75305.76% Upside

Current Analyst Ratings Breakdown

Latest PYXS, DSGN, AMRN, and ACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$5.00
9/3/2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$5.00
8/25/2025
Amarin Corporation PLC stock logo
AMRN
Amarin
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/19/2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
8/18/2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
8/8/2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell
6/25/2025
Amarin Corporation PLC stock logo
AMRN
Amarin
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSell$7.00 ➝ $12.00
(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.12$0.61 per share8.03$7.78 per share0.63
Amarin Corporation PLC stock logo
AMRN
Amarin
$228.61M1.39N/AN/A$23.62 per share0.65
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/A$4.28 per shareN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$16.15M7.33N/AN/A$2.03 per share0.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M-$0.19N/A11.16N/A-5.66%-1.49%-1.06%11/5/2025 (Estimated)
Amarin Corporation PLC stock logo
AMRN
Amarin
-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%10/29/2025 (Estimated)
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$49.59M-$1.12N/AN/AN/AN/A-27.15%-26.07%11/6/2025 (Estimated)
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$77.33M-$1.60N/AN/AN/AN/A-68.56%-52.14%11/11/2025 (Estimated)

Latest PYXS, DSGN, AMRN, and ACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.36-$0.30+$0.06-$0.30N/A$2.82 million
8/7/2025Q1 2025
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$0.32-$0.34-$0.02-$0.34N/AN/A
8/6/2025Q1 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.18-$0.19-$0.37-$0.20$96.83 million$71.98 million
7/30/2025Q2 2025
Amarin Corporation PLC stock logo
AMRN
Amarin
-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 million
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.06
2.97
1.51
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.26
2.34
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/A
25.13
25.13
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/A
5.65
5.65

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
56.64%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
39.09%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Amarin Corporation PLC stock logo
AMRN
Amarin
1.96%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
23.50%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
10.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.45 million56.45 millionOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
36020.68 million20.28 millionOptionable
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
4056.95 million43.57 millionOptionable
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
6062.02 million55.44 millionOptionable

Recent News About These Companies

Analysts Set Pyxis Oncology, Inc. (NASDAQ:PYXS) Price Target at $8.67
William Blair Forecasts Pyxis Oncology Q1 Earnings
Pyxis Oncology Inc News (PYXS) - Investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.91 +0.08 (+1.66%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$4.92 +0.01 (+0.20%)
As of 09/5/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Amarin stock logo

Amarin NASDAQ:AMRN

$15.33 +0.30 (+2.00%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$15.32 -0.01 (-0.07%)
As of 09/5/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Design Therapeutics stock logo

Design Therapeutics NASDAQ:DSGN

$6.45 +0.34 (+5.56%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$6.46 +0.01 (+0.16%)
As of 09/5/2025 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Pyxis Oncology stock logo

Pyxis Oncology NASDAQ:PYXS

$1.91 +0.30 (+18.63%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$1.97 +0.06 (+3.14%)
As of 04:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.